Issue 75, 2014

Cyclometalated Ir(iii) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy

Abstract

The successful design and anticancer mechanistic studies of a series of cyclometalated Ir(III) complexes with histone deacetylase inhibitory and photodynamic therapy (PDT) activities are reported.

Graphical abstract: Cyclometalated Ir(iii) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy

Supplementary files

Article information

Article type
Communication
Submitted
07 Jul 2014
Accepted
29 Jul 2014
First published
30 Jul 2014

Chem. Commun., 2014,50, 10945-10948

Cyclometalated Ir(III) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy

R. Ye, C. Tan, L. He, M. Chen, L. Ji and Z. Mao, Chem. Commun., 2014, 50, 10945 DOI: 10.1039/C4CC05215C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements